Really interesting here...
- be a little bit nervous, if still waiting around - to take a position in the company, pending this DIPG data release.
Why so ? Well this company, Day One Pharmaceuticals - also has its kids brain cancer study sponsored by The Pacific Pediatric Neuro-Oncology Consortium (PNOC)......Ony a few weeks ago - Day One just came out and made a data announcement for their FDA Trial - no waiting around for a conference presentation, just a simple stock exchange announcement.
Sent the market cap up by A$400 million or so - mind numbing, considering they had already been capped at a billion.
So we are entering into a "hold your breath period" for this company - given a previous delay in release of DIPG data, and the company clearly saying to expect it in July or August.
There would be great justification for a share price 15 times higher than currently - should DIPG data be positive - so 15 times, or A$400m cap, that is still pretty ridiculously cheap though.
ASCO: Day One Biopharma announces new FIREFLY-1 data for tovorafenib
06-06-2023
Day One Biopharmaceuticals (Nasdaq: DAWN) shares leapt 33.8% to $18.19 in pre-market trading on Monday, after the company announced overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pre-treated RANO-HGG evaluable patients in pediatric low-grade glioma trial.
Day One Bio shared the new data from its Phase II registrational FIREFLY-1 trial evaluating tovorafenib (DAY101) for relapsed or progressive pediatric low-grade glioma..........
- Forums
- ASX - By Stock
- KZA
- Comparisions other Drug Companies
Comparisions other Drug Companies, page-4
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)